Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) is described in its own communications as a leader in life science research and clinical diagnostics products. Based in Hercules, California, the company operates globally and regularly issues news on its financial performance, technology platforms, and corporate developments. This news page aggregates recent BIO stock headlines and company announcements.
Investors and analysts following Bio-Rad can find updates on quarterly financial results, including segment performance for the Life Science and Clinical Diagnostics groups and commentary on factors such as academic research funding, biotech funding conditions, and reimbursement trends in key markets. The company frequently discusses both GAAP and non-GAAP results, along with explanations of how non-GAAP measures are used in its internal analysis.
Bio-Rad’s news flow also covers product and technology updates, particularly around its Droplet Digital PCR (ddPCR) portfolio. Recent releases describe the launch of new ddPCR platforms, the integration of technologies from the acquisition of Stilla Technologies, and webinars or presentations focused on its ddPCR product line. These items provide insight into how the company is expanding its presence in genomics research and applied science applications.
Additional news items include announcements about participation in healthcare and investor conferences, leadership appointments, and historical and corporate milestones. For example, the company has reported on executive leadership changes and has issued statements regarding the passing of its co-founder and Director Emeritus, Alice N. Schwartz. Users interested in BIO news can use this page to review these updates in one place and to track how Bio-Rad communicates its strategy and operations over time.
Bio-Rad Laboratories will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. Pacific Time. CEO Norman Schwartz will lead the company overview, followed by a Q&A with Andrew Last and Ilan Daskal, Bio-Rad's Executive Vice Presidents. The event will be available via a webcast on Bio-Rad's website.
Bio-Rad Laboratories (NYSE: BIO and BIO.B) announced that its management will participate in a Fireside Chat during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST). A live webcast will be accessible on the company's Investor Relations webpage at bio-rad.com. Bio-Rad, based in Hercules, California, is a leader in life science research and clinical diagnostics, with approximately 8,200 employees and $2.9 billion in revenue for 2021.
Bio-Rad Laboratories reported Q3 2022 net sales of $680.8 million, down 8.9% from Q3 2021. COVID-related revenue declined to $17 million from $57 million in the previous year. The Life Science segment saw a 14.9% decrease in net sales, while Clinical Diagnostics dipped 2.8%. The company posted a net loss of $164.2 million, or $5.52 per share, compared to net income of $3.9 billion or $129.96 per share in Q3 2021. The non-GAAP outlook for 2022 anticipates currency-neutral revenue growth at the high end of 1-2% guidance.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its third-quarter 2022 financial results on October 27, 2022, after market close. A conference call discussing these results is scheduled for 2 PM Pacific Time the same day. Bio-Rad, a leader in life science research and clinical diagnostics, generated $2.9 billion in revenues for 2021 and employs approximately 7,900 individuals worldwide. Investors can access a live webcast via the 'Investor Relations' section of the company's website.
Bio-Rad Laboratories (NYSE: BIO) has announced the acquisition of Curiosity Diagnostics for up to $170 million, comprising $100 million in cash and $70 million in future milestones. Curiosity, based in Poland, is developing a rapid diagnostics PCR system for the molecular diagnostics market. This acquisition aims to enhance Bio-Rad's Clinical Diagnostics Group, expanding into near-patient molecular diagnostics. With Bio-Rad's extensive market presence and Curiosity's innovative technology, the deal is anticipated to improve product offerings and market reach.
Bio-Rad Laboratories (NYSE: BIO, BIO.B) reported Q2 2022 net sales of $691.1 million, down 3.5% year-over-year, with COVID-related revenue falling to approximately $33 million. Currency-neutral sales recorded a 0.5% increase. Life Science segment sales decreased by 3.5% to $322.4 million, while Clinical Diagnostics fell 3.3% to $367.8 million. A significant net loss of $927.2 million was reported versus a net income of $914.1 million in Q2 2021, largely due to equity securities valuation changes. The full-year outlook remains positive with expected revenue growth and an increased share repurchase program of $200 million.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q2 2022 on July 28, 2022, after market close. A conference call is scheduled for 3 PM Pacific Time (6 PM Eastern Time) to discuss these results. Investors can participate by calling 844-200-6205 within the U.S. or +1 929-526-1599 internationally, access code: 715914. A live webcast will also be available.
Summary not available.
Bio-Rad Laboratories, Inc. reported Q1 2022 net sales of $700.1 million, down 3.7% from Q1 2021. Excluding COVID-related sales, revenue increased 6.5% on a currency-neutral basis, driven by strong growth in Process Media and Droplet Digital PCR products. The net loss for the quarter was $3.37 billion or $112.57 per share, significantly impacted by changes in the fair market value of equity securities. Non-GAAP net income was $149.1 million, or $4.94 per diluted share. The company anticipates 1.0% to 2.0% revenue growth for FY 2022.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q1 2022 on April 28, 2022, after the market closes. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). The company, a leader in life science research and clinical diagnostics, had revenues of $2.9 billion in 2021 and has been operational since 1952, serving a global customer base focused on advancing healthcare.